Abstract
The metabolic syndrome consists of a clustering of metabolic derangements that cause the affected individual to have an increased risk for developing cardiovascular disease. Dyslipidemia is an important component of the metabolic syndrome and is included in all the definitions of the metabolic syndrome published by different international committees to identify individuals with the metabolic syndrome. Atherogenic dyslipidemia in the metabolic syndrome comprises of hypertriglyceridemia, low levels of high-density lipoprotein cholesterol and a preponderance of small dense low-density lipoprotein particles. The pathogenesis of dyslipidemia in the metabolic syndrome will be reviewed and the roles of therapeutic lifestyle modification and drug therapies in the treatment of dyslipidemia will be discussed.
Keywords: Metabolic syndrome, dyslipidemia, hypertriglyceridemia, small dense LDL, insulin resistance
Cardiovascular & Hematological Disorders-Drug Targets
Title: Management of Dyslipidemia in the Metabolic Syndrome
Volume: 7 Issue: 2
Author(s): Kathryn C. B. Tan
Affiliation:
Keywords: Metabolic syndrome, dyslipidemia, hypertriglyceridemia, small dense LDL, insulin resistance
Abstract: The metabolic syndrome consists of a clustering of metabolic derangements that cause the affected individual to have an increased risk for developing cardiovascular disease. Dyslipidemia is an important component of the metabolic syndrome and is included in all the definitions of the metabolic syndrome published by different international committees to identify individuals with the metabolic syndrome. Atherogenic dyslipidemia in the metabolic syndrome comprises of hypertriglyceridemia, low levels of high-density lipoprotein cholesterol and a preponderance of small dense low-density lipoprotein particles. The pathogenesis of dyslipidemia in the metabolic syndrome will be reviewed and the roles of therapeutic lifestyle modification and drug therapies in the treatment of dyslipidemia will be discussed.
Export Options
About this article
Cite this article as:
B. Tan C. Kathryn, Management of Dyslipidemia in the Metabolic Syndrome, Cardiovascular & Hematological Disorders-Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/187152907780830860
DOI https://dx.doi.org/10.2174/187152907780830860 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial Targeting for Development of Novel Drug Strategies in Brain Injury
Central Nervous System Agents in Medicinal Chemistry Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology Increased Exercise Favorably Modifies Coronary Artery Disease and Peripheral Arterial Disease Outcomes
Current Vascular Pharmacology Editorial [ Hot Topic: Antidepressant Drug Design (Executive Editor: Lee E. Schechter)]
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Vascular Pharmacology Interactions Between Plasma Proteins and Naturally Occurring Polyphenols
Current Drug Metabolism The Brain, the Penis and Steroid Hormones: Clinical Correlates with Endothelial Dysfunction
Current Pharmaceutical Design Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry Beta-Blockers for the Treatment of Essential Hypertension: What are the Arguments Against Their Use as First Line Therapy?
Current Hypertension Reviews Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Alterations in Plasma Triglyceride Concentrations Following Two Oral Meals with Different Fat Content in Patients with Type 2 Diabetes Mellitus
Current Vascular Pharmacology Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews Insight to the Pathophysiology of Stable Angina Pectoris
Current Pharmaceutical Design Elevated Heart Rate, A Risk Factor and Risk Marker of Cardiovascular Disease
Current Hypertension Reviews Oxidative Stress and Endothelial Dysfunction in Cardiovascular Disease: Mitochondria-Targeted Therapeutics
Current Medicinal Chemistry Evaluation of Blood Pressure Control using a New Arterial Stiffness Parameter, Cardio-ankle Vascular Index (CAVI)
Current Hypertension Reviews Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Human Heart Cardiomyocytes in Drug Discovery and Research: New Opportunities in Translational Sciences
Current Pharmaceutical Biotechnology Hematologic Abnormalities in the Antiphospholipid Syndrome
Current Rheumatology Reviews Cigarette Smoking and Hypertension
Current Pharmaceutical Design